Symbiotec Pharmalab IPO GMP today is TBA. Investors can use this GMP along with price band and subscription status for a better IPO review.
Upcoming
Mainboard IPO
SYMBIOTEC
Symbiotec Pharmalab
Symbiotec Pharmalab Limited is a pharmaceutical company engaged in developing and manufacturing active pharmaceutical ingredients (APIs), contract development and manufacturing (CDMO) solutions, and complex injectables. The company operates an integrated business model supported by research and development, fermentation, and organic chemistry capabilities. Its API portfolio primarily focuses on steroidal products, while its CDMO business offers development and manufacturing services for pharmaceutical, nutraceutical, and other life science companies. The company also develops complex injectable products, including double-chamber formats, and leverages its in-house API capabilities to support these offerings. Revenue is generated through the sale of APIs, CDMO services, and complex injectable products. Its business is supported by backward integration in key raw material processing, large-scale fermentation capacity, and multiple manufacturing facilities, enabling it to serve customers across regulated and global markets while expanding into new therapeutic and fermentation-based product categories.
IPO Details
Complete IPO information
| Current GMP | - |
|---|---|
| Estimated Listing Gain | TBA |
| Price Band | TBA |
| Issue Price | TBA |
| Listing Price | TBA |
| Lot Size | TBA |
| Issue Type | Mainboard |
| Issue Size | Approx ₹2,180 Cr |
| Registrar | TBA |
| Exchange | NSE, BSE |
| Retail Quota | TBA |
| Overall Subscription | TBA |
| Listing Date | TBA |
| Minimum Investment | TBA |
Timeline
IPO roadmap at a glance
01
Bidding Opens
TBA
02
Bidding Closes
TBA
03
Allotment
TBA
04
Listing
TBA
Market Lot
Application size breakdown
| Category | Lots | Shares | Amount |
|---|---|---|---|
| Retail Minimum | - | - | - |
| Retail Maximum | - | - | - |
| S-HNI Minimum | - | - | - |
| S-HNI Maximum | - | - | - |
| B-HNI Minimum | - | - | - |
Issue Notes
Important takeaways before applying
Strengths
- Operates an integrated business across APIs, CDMO services and complex injectables.
- Has one of India’s largest industrial-scale fermentation capacities with 700 KL capacity.
- Backward integration reduces dependence on external sources for key intermediates.
- Develops differentiated double-chamber injectable products using in-house API capabilities.
- Long-term manufacturing agreements and strategic partnerships support future business growth.
Risks
- Almost all revenue comes from API products, making the business dependent on API demand.
- A large share of revenue comes from a few key customers, and losing them could hurt the business.
- The company depends on key suppliers for raw materials, and supply disruptions could affect operations.
- The company faces intense competition in both the API and CDMO businesses.
- Failure to meet repayment obligations or loan covenants could adversely affect the business and finances.
FAQ
Symbiotec Pharmalab IPO FAQs
Symbiotec Pharmalab IPO price band is TBA. Check the latest issue price, lot size and GMP together before applying.
Symbiotec Pharmalab IPO open date is TBA, close date is TBA, and listing date is TBA.
Symbiotec Pharmalab IPO lot size is TBA. The minimum retail investment is TBA.
Symbiotec Pharmalab is classified as a Mainboard. This helps investors quickly understand the issue category and exchange segment.
Symbiotec Pharmalab IPO subscription status currently shows Subscription data is currently awaited.
Symbiotec Pharmalab Limited is a pharmaceutical company engaged in developing and manufacturing active pharmaceutical ingredients (APIs), contract development and manufacturing (CDMO) solutions, and complex injectables. The company operates an integrated business model supported by research and development, fermentation, and organic chemistry capabilities. Its API portfolio primarily focuses on steroidal products, while its CDMO business offers development and manufacturing services for pharmaceutical, nutraceutical, and other life science companies. The company also develops complex injectable products, including double-chamber formats, and leverages its in-house API capabilities to support these offerings. Revenue is generated through the sale of APIs, CDMO services, and complex injectable products. Its business is supported by backward integration in key raw material processing, large-scale fermentation capacity, and multiple manufacturing facilities, enabling it to serve customers across regulated and global markets while expanding into new therapeutic and fermentation-based product categories.
Symbiotec Pharmalab IPO issue size is 2180 and the expected allotment date is TBA.